Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Perovskite Solar Cells Based on Oligotriarylamine Hexaarylbenzene as Hole-Transporting Materials.

Shasti M, Völker SF, Collavini S, Valero S, Ruipérez F, Mortezaali A, Zakeeruddin SM, Grätzel M, Hagfeldt A, Delgado JL.

Org Lett. 2019 May 3;21(9):3261-3264. doi: 10.1021/acs.orglett.9b00988. Epub 2019 Apr 22.

PMID:
31007029
2.

Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process.

Valero S, López-Briz E, Vila N, Solana A, Melero M, Poveda JL.

Regul Toxicol Pharmacol. 2018 Jun;95:1-7. doi: 10.1016/j.yrtph.2018.03.001. Epub 2018 Mar 3.

PMID:
29510165
3.

Organic and perovskite solar cells: Working principles, materials and interfaces.

Marinova N, Valero S, Delgado JL.

J Colloid Interface Sci. 2017 Feb 15;488:373-389. doi: 10.1016/j.jcis.2016.11.021. Epub 2016 Nov 11. Review.

PMID:
27871725
4.

Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial.

Llibre JM, Alvarez H, Antela A, Toro J, Payeras A, Pérez-Elías MJ, Imaz A, Masià M, Pérez-Alvarez N, Burgos J, Clotet B; Members of the Nuke-Out Study.

J Antimicrob Chemother. 2016 May;71(5):1346-51. doi: 10.1093/jac/dkv461. Epub 2016 Jan 23.

PMID:
26803719
5.

Hyperspectral image representation and processing with binary partition trees.

Valero S, Salembier P, Chanussot J.

IEEE Trans Image Process. 2013 Apr;22(4):1430-43. doi: 10.1109/TIP.2012.2231687. Epub 2012 Dec 4.

PMID:
23221824
6.

Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: results from a study on patient and physician perceptions.

Cabrero E, Griffa L, Burgos A; HIV Body Physical Changes Study Group.

AIDS Patient Care STDS. 2010 Jan;24(1):5-13. doi: 10.1089/apc.2009.0191.

PMID:
20095903
7.

Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.

Moltó J, Deig E, Valle M, Maria Llibre J, Miranda C, Cedeño S, Valero S, Negredo E, Clotet B.

Ther Drug Monit. 2010 Feb;32(1):93-6. doi: 10.1097/FTD.0b013e3181cb479f.

PMID:
20040897
8.

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.

Martínez E, Larrousse M, Podzamczer D, Pérez I, Gutiérrez F, Loncá M, Barragán P, Deulofeu R, Casamitjana R, Mallolas J, Pich J, Gatell JM; BICOMBO Study Team.

AIDS. 2010 Jan 28;24(3):F1-9. doi: 10.1097/QAD.0b013e32833562c5.

PMID:
20009917
9.

Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.

Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF; MONARK Study Group.

HIV Med. 2010 Feb;11(2):137-42. doi: 10.1111/j.1468-1293.2009.00752.x. Epub 2009 Aug 13.

10.

Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shürmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C; MONARK Study Group.

Antimicrob Agents Chemother. 2009 Jul;53(7):2934-9. doi: 10.1128/AAC.01643-08. Epub 2009 May 18.

11.

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, Ribera E, Knobel H, Roca V, Gutiérrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosín J, Barrufet P, Casas E, Ferrer E, Curran A, González A, Pich J, Cruceta A, Arnaiz JA, Miró JM, Gatell JM; BICOMBO Study Team.

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):290-7. doi: 10.1097/QAI.0b013e3181aa12d5.

PMID:
19398921
12.

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM; ATAZIP Study Group.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f.

PMID:
19390327
13.

Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.

Moltó J, Llibre JM, Ribera E, Mínguez C, del Río JS, Pedrol E, Vallecillo G, Cedeño S, Valle M, Miranda C, Negredo E, Clotet B; SQV-HEP Study Group.

J Antimicrob Chemother. 2009 May;63(5):992-7. doi: 10.1093/jac/dkp070. Epub 2009 Mar 11.

PMID:
19279052
14.

Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

Santin M, Shaw E, Garcia MJ, Delejido A, de Castro ER, Rota R, Altés J, Baguena F, Valero S, Sala M, Casanova A; HCV/HIV-01 Study Team.

AIDS Res Hum Retroviruses. 2006 Apr;22(4):315-20.

Supplemental Content

Loading ...
Support Center